The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis

NCT06773221 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

195

Enrollment

OTHER

Sponsor class

Conditions

Metabolic Dysfunction Associated Fatty Liver Disease
Compensated Liver Cirrhosis

Interventions

DRUG: Chiglitazar 64mg
DRUG: Placebo

Sponsor

Beijing Friendship Hospital

Collaborators

[object Object]
[object Object]
[object Object]